Reading this on a mobile device? Try our optimized mobile version here:

October 11, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Panel urges greater genome sequencing privacy protection
    Whole genome sequencing offers enormous promise for enhancing medical care and is helping researchers identify the genetic causes of rare diseases, but it raises privacy issues, according to the report "Privacy and Progress in Whole Genome Sequencing," by the Presidential Commission for the Study of Bioethical Issues. The commission recommended creating "clear policies" on who has access to whole genome data and how it can be used, as well as informing patients of the consequences and risks of sequencing. blog (10/11), USA TODAY (10/11) LinkedInFacebookTwitterEmail this Story
  Health Care & Policy 
  • Global Alzheimer's trial will study Roche, Lilly drugs
    Experimental Alzheimer's drugs from Roche Holding and Eli Lilly and Co. will be studied in a global trial of 160 patients with genetic indicators that they are prone to the disease. The study, set to begin next year, will include Roche's gantenerumab and Lilly's solanezumab, and a beta-secretase inhibitor from Lilly could be added. Reuters (10/10) LinkedInFacebookTwitterEmail this Story
  • Nobel goes to physicians for research on how drugs work
    Dr. Robert Lefkowitz, a professor of biochemistry, pathology and medicine at Duke University Medical Center and an investigator for the Howard Hughes Medical Institute, as well as Dr. Brian Kobilka, a professor of molecular and cellular physiology and medicine at Stanford University, received the Nobel Prize in Chemistry for their work on how cells identify and react to hormones. About half of drugs work through G-protein-coupled receptors, and the Lefkowitz and Kobilka's work could lead to treatments with fewer side effects. The Christian Science Monitor (10/10) LinkedInFacebookTwitterEmail this Story
  • GSK and Aeras plan multinational trial of TB vaccine
    Nonprofit biotech group Aeras and GlaxoSmithKline aim to initiate next year a Phase IIb study to evaluate the efficacy of an investigational tuberculosis vaccine in India, Kenya and South Africa. The trial, subject to regulatory approval, would involve healthy adults ages 18 to 50. The vaccine is designed to be used in combination with Bacille Calmette-Guerin, an existing TB vaccine. Reuters (10/10) LinkedInFacebookTwitterEmail this Story
  • MannKind's insulin Afrezza enters 2 late-stage trials
    MannKind completed recruitment in two Phase III studies of insulin Afrezza. "Both studies are on track to be completed in the second quarter of 2013, and we expect to report top-line results next summer," Chairman and CEO Alfred Mann said. "Our objective is to resubmit the [new-drug application] for Afrezza in the third quarter of next year." Pharmaceutical Business Review Online (10/8) LinkedInFacebookTwitterEmail this Story
Top 8 Obstacles in Pharma & Biologics Product Registration & Submission Management
For pharmaceutical and biologics companies, the path to a global product launch is full of obstacles that could result in delays to registrations, many of which can be avoided with the help of automation. This white paper identifies some of the most common problems in managing submissions for the purpose of product registration and how best to address them. Download the whitepaper.
  Company & Financial News 
  • Genocea pulls in $30M to advance 2 vaccine candidates
    Genocea Biosciences secured $30 million in a Series C financing round from existing and new investors, including the Bill & Melinda Gates Foundation. The firm will use the proceeds to further develop an experimental therapeutic vaccine for herpes simplex virus type 2 and an early-stage vaccine against infections caused by Streptococcus pneumoniae. American City Business Journals/Boston (10/10) LinkedInFacebookTwitterEmail this Story
  Industry Deals 
  Food & Agriculture 
  • Vilmorin ends plans to test biotech crops in France
    Vilmorin & Cie has decided not to carry out field trials of biotech crops in France next year, but it will continue the tests in Spain and two other nations in Europe. "The political climate led us to put the question on hold for now," Vilmorin Chief Financial Officer Daniel Jacquemond said. Biotech crops "are absolutely essential components for the competitiveness of agriculture including Europe," Jacquemond said. Reuters (10/10) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • BIO: Altering RFS would impede advanced biofuels development
    Suspending the Renewable Fuel Standard would undercut the development of advanced biofuel, writes BIO president and CEO Jim Greenwood. "Rushing into long-term policy changes to the RFS could have an unintended economic impact on family farmers, biofuel producers and consumers. Additionally, waiving the RFS requirement could reduce the momentum that has been building toward producing other second-generation fuels," Greenwood writes. The Hill/Congress Blog (10/10) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Action may not always bring happiness; but there is no happiness without action."
--Benjamin Disraeli,
British politician

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information